A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-5)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms EXPEDITION-5
- Sponsors AbbVie
- 31 Oct 2017 Planned End Date changed from 11 May 2018 to 4 Jun 2018.
- 31 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Sep 2017 Planned End Date changed from 28 Apr 2018 to 11 May 2018.